spacer
home > ict > autumn 2016 > lessons learned
PUBLICATIONS
International Clinical Trials

Lessons Learned

When validating the one million data points that compose a typical Phase 3 trial, focusing on irrelevant mistakes could easily result in wasted resources. The industry’s initial response – in the form of risk-based monitoring (RBM) – detects errors and risks more efficiently, but can still expend resources on errors not pertinent to a study’s validity and, therefore, miss opportunities to define and solve critical quality issues.

What if we were to look to other industries’ strategies for risk mitigation, in order to evolve RBM into a more useful approach for protecting clinical data? One of these methodologies – namely human factor analysis (HFA) – is employed by NASA, Ford, the US Environmental Protection Agency, major airlines and several countries’ militaries to identify and mitigate human error in large, variously trained workforces. Closer to the pharmaceutical sector, human factors are the core to the foundation training by the WHO in its education on patient safety (1). HFA uses uniquely structured datasets to show underlying behaviours that are otherwise difficult for humans to sense or reconstruct but are, ultimately, the root cause of an incident.

Consider a site that has multiple issues with informed consent. A traditional monitoring approach would log a problem, potentially announce the site as high risk and deploy general retraining on informed consent. Instead, using HFA allows one to look for trends in the data and classify what they revealed in predetermined categories; for instance, consent errors became more frequent after that site had enrolled 100 or more patients. To mitigate risk, the project team could perhaps limit the site to no more than 75 patients and provide additional investigator support focusing on resource allocation.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Clara Heering is Senior Vice President of Clinical Risk and Data Management at ICON, and has over 20 years’ experience in clinical research, which spans both CRO and pharma industries. Clara's previous experience includes 16 years at Pfizer and two years as Research Fellow at Harvard Medical School, US. She holds a degree in Risk Management and in Medical Biology.
spacer
Clara Heering
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>

White Papers

Achieve full compliance with tamper-verification pharma solutions

UPM Raflatac

UPM Raflatac has developed a range of pharmaceutical labelling products to support compliance with the Falsified Medicines Directive on packaging for prescription drugs and high-risk, over-the-counter medicines. Few solutions offer the same ease of adoption for meeting the February 2019 deadline.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement